Ceracal 30 Tablet

Manufactured byBIOCON LTD
ContainsCinacalcet
Description

Ceracal 30 Tablet is a calcimimetic agent, a drug that mimics or copies the actions of calcium on the tissues. It is used to treat secondary hyperparathyroidism as well as hypercalcemia (high blood calcium levels). This medicine is not recommended for use in patients less than 18 years of age.

Substitutes

List of substitutes for Ceracal 30 Tablet

Side effects

Major & minor side effects for Ceracal 30 Tablet

  • Blurred vision
  • Chest pain
  • Nervousness
  • Headache
  • Difficult or painful urination
  • Fever or chills
  • Lower back or side pain
  • Muscle spasm
  • Dizziness

Uses of Ceracal 30 Tablet

What is it prescribed for?

  • Secondary Hyperparathyroidism
  • Hypercalcemia of malignancy
  • Primary Hyperparathyroidism
Read More
Concerns

Commonly asked questions

  • Onset of action
    The peak effect of this medicine can be observed within 2 to 6 hours of administration of the dose.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue the medicine or to discontinue breastfeeding based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to cinacalcet or any other inactive ingredients present along with this medicine.

Hypocalcemia

This medicine is not recommended for use in patients suffering from hypocalcemia (low blood calcium levels) due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue the medicine or to discontinue breastfeeding based on your clinical condition.
General warnings

Chronic Kidney Disease

This medicine is not recommended for use in patients suffering from chronic kidney disease who are not being treated with dialysis due to the increased risk of hypocalcemia (low blood calcium levels). Replacement with a suitable alternative should be considered based on the clinical condition.

Gastrointestinal Bleeding

This medicine should be used with caution in patients suffering from gastrointestinal bleeding or patients susceptible to gastrointestinal bleeding due to the increased risk of worsening of the patient's condition. Report any unusual symptoms to the doctor on priority. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition of the patient.

Adynamic bone disease

This medicine should be used with extreme caution since the suppression of parathyroid hormone levels beyond a certain limit (100 pg/ml) may increase the risk of adynamic bone disease. Regular monitoring of parathyroid hormone levels is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition of the patient.

Monitoring of Hypocalcemia

Patients receiving this medicine should be closely monitored for hypocalcemia (low blood calcium levels). Serum calcium levels should be measured within 1 week of beginning therapy as well as any dose changes. Once a maintenance dose is established, serum calcium levels should be monitored approximately monthly unless the patient experiences any unusual symptoms. Report any unusual symptoms such as muscle spasms, seizures, shortness of breath, changes in heat rate, etc. to the doctor immediately. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Use in pediatrics

This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established. Your doctor may prescribe this medicine in specific cases if the benefits significantly outweigh the risks. If the medicine is used, the patient should be monitored closely for any undesirable side effects.

Driving or Operating machinery

Use of this medicine may cause symptoms such as blurred vision, dizziness, drowsiness, etc. in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed dose.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Amitriptyline

Pimozide

Carvedilol

Clarithromycin

Tamoxifen

Thioridazine

Fluvoxamine

Disease interactions

Seizures

This medicine should be used with extreme caution in patients suffering from seizures due to the increased risk of worsening of the patient's condition. Regular monitoring of serum calcium levels is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.

Hypotension

This medicine should be used with caution in patients suffering from preexisting hypotension (low blood pressure) since it may increase the risk of worsening of the patient's condition. Close monitoring of blood pressure levels, appropriate dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
Food interactions
Information not available.
Lab interactions
Information not available.
Take this medicine with food or immediately after food. Do not take in larger or smaller amounts than advised/prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken with food

To be taken as instructed by doctor

May cause sleepiness

How it works
It acts on the parathyroid glands to lower the levels of parathyroid hormone and calcium in the body.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Calcimimetics

Schedule

Schedule H

Cinacalcet - DrugBank [Internet]. Drugbank.ca. 2018 [cited 27 July 2018]. Available from:

https://www.drugbank.ca/drugs/DB01012

Cinacalcet: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2018 [cited 27 July 2018]. Available from:

https://medlineplus.gov/druginfo/meds/a605004.html

Mimpara tablets - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2018 [cited 27 July 2018]. Available from:

https://www.medicines.org.uk/emc/product/5599/smpc#

[Internet]. Pi.amgen.com. 2018 [cited 27 July 2018]. Available from:

https://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/sensipar/sensipar_pi_hcp_english.ashx

TGA eBS - Product and Consumer Medicine Information Licence [Internet]. Ebs.tga.gov.au. 2018 [cited 27 July 2018]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05724-3&d=2018072716114622483
Loading related questions...

How will this medicine affect me?

Chat with verified doctors starting @ ₹99
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Something doesn’t feel right?
Report an error